Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. - McDonald BR; Contente-Cuomo T; Sammut SJ; Odenheimer-Bergman A; Ernst B; Perdigones N; Chin SF; Farooq M; Mejia R; Cronin PA; Anderson KS; Kosiorek HE; et al. (Science translational medicine, 2019)